Skip to main content
Premium Trial:

Request an Annual Quote

Luminex, Abbott Strike R&D and Supply Deals

NEW YORK, Jan. 15-Abbott Laboratories will develop and distribute assays and instruments using Luminex's bead-based xMAP technology, the two companies said today.

 

The companies have signed two agreements that grant Abbott the right to license, supply and distribute Luminex biological testing technologies, develop new products, and purchase and distribute existing Luminex products.

 

Luminex will receive an upfront license fee from Abbott and royalties on commercialized assays and instruments. Abbott will also directly purchase Luminex 100 systems and xMAP microspheres.

 

The company's xMAP system, which is based on microsphere analysis, allows for medium- and high-throughput multiplexed assays.

 

Luminex, based in Austin, Tex., is publicly held.

 

For further information, see the company statement.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.